尼塞韦单抗的第二季影响：第一季接种疫苗患者呼吸道合胞病毒疾病的临床结局
Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.
作者信息
González-Bertolín Isabel, Alcolea Sonia, Alonso Patricia, Arroyas María, Fernández Castiella Isabel, Echavarren Iciar, Iglesias-Caballero Maria, Casas Inmaculada, García-García María Luz, Calvo Cristina
机构信息
From the Pediatrics and Infectious Disease Department, La Paz University Hospital, IdiPaz Foundation, Madrid.
Pediatric Department, Severo Ochoa University Hospital, Leganés.
出版信息
Pediatr Infect Dis J. 2025 Aug 22;44(10):1009-11. doi: 10.1097/INF.0000000000004920.
Nirsevimab provides passive immunization against respiratory syncytial virus, yet concerns exist regarding its long-term impact. This study analyzed respiratory syncytial virus-associated lower respiratory tract infection severity in hospitalized children immunized with nirsevimab more than 6 months prior. No significant differences were found compared with nonimmunized children. Findings suggest no increased risk in the following season, supporting nirsevimab's safety as a preventive strategy.
尼塞维单抗可提供针对呼吸道合胞病毒的被动免疫，但人们对其长期影响仍存在担忧。本研究分析了在6个月多前接种尼塞维单抗的住院儿童中与呼吸道合胞病毒相关的下呼吸道感染严重程度。与未接种疫苗的儿童相比，未发现显著差异。研究结果表明在下个季节风险没有增加，这支持了尼塞维单抗作为一种预防策略的安全性。
Zotero 插件